John Whelan: Ireland behind the curve in pharma R&D amid Pfizer call
Pharma companies met with the Trump administration earlier this month to try and defer implementation of the executive order signed by President Trump on May 12, effectively forcing drug companies to commit to aligning their US prices with 'the lowest price of a set of economic peer countries''.
At the meeting of the Pharmaceutical Research and Manufacturers of America (PhRMA) with the Trump administration, Pfizer chief executive Albert Bourla called for the US government to lead an initiative to increase overall drug spending outside the US.
While the exact mechanism of implementing the Trump executive order to reduce drug prices in the US remains unclear, the Pfizer chief proposed an alternative solution, suggesting that other countries should spend a certain percentage of their GDP per capita on innovative medicines.
In an attempt to lead on the recommendation, he added that Pfizer could consider not making its drugs available for government reimbursement in some countries if the US carries through on its price control and other countries don't increase their prices.
Effectively, Mr Bourla, who chairs the pharma industry lobby group PhRMA, suggested the US should push for a Nato-type agreement, which commits each country to a minimum 2% of their national GDP on defence spending.
And whereas there may be good logic in the Pfizer proposal, any commitment of this nature will likely create major challenges for Ireland, as OECD and World Bank figures show Ireland lagging well behind other countries in research and development expenditure.
In 2022, the last year for which finalised figures have been released, US pharmaceutical companies' R&D spending amounted to 2.33% of the nation's GDP.
There is no comparable figures for the Irish market, in terms of pharmaceutical industry expenditure in research and development. However, the figures available from the World Bank and the OECD for years 2022/2023 show that total R&D for all industry as a percentage of GDP, in Ireland was 0.9%. This is well below the EU average of 2.29%, and even further below countries like the US at 3.6% and Israel at 6.3% who invest more heavily in R&D than Ireland.
Economists have inferred that Trump is leveraging unfavourable policies such as drastically lowering prices points of US drugs and tariffs on imports, to coerce the pharmaceutical industry to increase investments in the US.
Several large pharma companies, including Eli Lilly, Merck & Co, and Bristol Myers Squibb, have unveiled major US investments planned for the next few years in attempt to curry favour with the Trump administration. But noticeably Pfizer remains an exception to that trend.
However, Mr Bourla stated that Pfizer has invested in US manufacturing and will continue to do so, but risks from those Trump policies are making it difficult for the company to commit further. "I don't think it makes sense to make announcements of future investments in an environment that is very fluid,' Mr Bourla said.
That suggests Pfizer, one of our largest and longest-term investors in the pharmaceuticals space, is unlikely to back off its Irish investments anytime soon. However , we need to heed the Pfizer CEO's call for more R&D support in Europe, which clearly includes Ireland.
Besides Pfizer, many pharma companies are leveraging the United States' threat of tariffs on drug imports to push for policy changes in the EU. In a letter sent on April 11 to European Commission President Ursula von der Leyen, 32 pharma companies demanded more favourable policies in order for them to maintain operations in the EU . In the same letter they say that policy changes are needed to ensure Europe remains a location to research, develop, and manufacture medicines.
The CEOs also included in their letter that European countries should rethink their drug pricing policies and enable a better commercial environment for innovative medicines.
Ireland's Research and Innovation Act 2024 , replaces Science Foundation Ireland in an attempt to fast forward the provision for the funding of research and innovation, but this caters for all fields of activity and neither commits to double the level of funding to €2bn per year needed to reach EU level, nor does it commit to meet the specific requirements of the pharma industry.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
20 minutes ago
- Irish Examiner
Iran issues stark warning to Trump 'the gambler': We will end this war
Iran said on Monday that the US attack on its nuclear sites expanded the range of legitimate targets for its armed forces and called US president Donald Trump a "gambler" for joining Israel's military campaign against the Islamic Republic. Ebrahim Zolfaqari, spokesperson for Iran's Khatam al-Anbiya central military headquarters, said the US should expect heavy consequences for its actions. "Mr Trump, the gambler, you may start this war, but we will be the ones to end it," Zolfaqari said in English at the end of a recorded video statement. Iran and Israel traded air and missile strikes as the world braced for Tehran's response to the US attack on its nuclear sites over the weekend, which Trump suggested could lead to the overthrow of the Iranian government. Commercial satellite imagery indicated Saturday's attack on Iran's Fordow nuclear plant far underground had severely damaged or destroyed the site and the uranium-enriching centrifuges it housed, but its status remained unconfirmed, experts said. In his latest social media comments on the US strikes, Trump said: "Monumental Damage was done to all Nuclear sites in Iran." "The biggest damage took place far below ground level. Bullseye!!!" he wrote on his Truth Social platform. Trump earlier called on Iran to forgo any retaliation and said the government "must now make peace" or future attacks would be "far greater and a lot easier", fuelling global concern about further escalation of conflict in the Middle East. This satellite picture by Planet Labs PBC shows Iran's underground nuclear enrichment site at Fordo on March 19, 2025. (Planet Labs PBC via AP) The US launched 75 precision-guided munitions including bunker-buster bombs and more than two dozen Tomahawk missiles against three Iranian nuclear sites, the chairman of the Joint Chiefs of Staff, General Dan Caine, told reporters. The UN nuclear watchdog, the International Atomic Energy Agency, said no increases in off-site radiation levels had been reported after the US strikes. Rafael Grossi, the agency's director general, told CNN that it was not yet possible to assess the damage done underground. A senior Iranian source told Reuters that most of the highly enriched uranium at Fordow had been moved elsewhere before the attack. Reuters could not immediately corroborate the claim. Tehran, which denies its nuclear programme is for anything other than peaceful purposes, launched a volley of missiles towards Israel in the aftermath of the US attack, wounding scores of people and destroying buildings in Tel Aviv. But it has not acted on its main options for retaliation, to attack US bases or choke off the 20% of global oil shipments that pass through the Strait of Hormuz. Attempting to strangle the strait could send global oil prices skyrocketing, derail the world economy and invite conflict with the US Navy's massive Fifth Fleet based in nearby Bahrain.
Irish Examiner
an hour ago
- Irish Examiner
Healthcare real estate firm Assura recommends €2bn takeover bid
British healthcare real estate investor Assura on Monday recommended rival Primary Health Properties' new £1.79bn (€2.09bn) takeover bid that trumps a lower offer from KKR and Stonepeak Partners. Assura has extensive operations in the UK before entering the Irish market three years ago. It has been responsible for developing primary care centres and other healthcare facilities in counties including Mayo, Cavan, Monaghan, and Offaly. Primary Health Properties's (PHP) latest 53.3p per share bid was higher than KKR-Stonepeak's "best and final" offer of 52.1p tabled earlier this month, and at a 47% premium to Assura's closing price before KKR-Stonepeak's first approach. Assura shareholders would get 0.3865 new PHP shares, 12.5p in cash, and be entitled to a special dividend of 0.84 pence per share under the terms of the latest bid, the companies said. The private equity firms and PHP have been competing over Assura for months, gradually sweetening their offers for the company which manages over 600 healthcare properties and counts Britain's state-backed National Health Service as a customer. Reuters
Irish Independent
an hour ago
- Irish Independent
Revealed: Shankill Butcher's cousin leads far-right protests in Dublin and Limerick
A loyalist ex-prisoner and cousin of a notorious Shankill Butchers cut-throat killer is leading Irish far-right protests, it has been revealed.
